Established in 1999, Cyprotex Limited was acquired by Evotec in 2016.
Cyprotex, an Evotec company, has sites at Alderley Park near Macclesfield, UK and in Watertown near Boston, USA. The company has dedicated and highly qualified employees with proven experience in a wide range of specialist techniques acquired across diverse industries. The majority of our clients focus in pharmaceutical research, however, we also support clients in the chemical, cosmetics and personal care and agrichemical tobacco industries.
Cyprotex specialises in in vitro and in silico ADME-Tox services. This includes in vitro ADME screening to support discovery projects, regulatory in vitro ADME and DDI studies during preclinical and clinical development, specialist mechanistic in vitro human and animal toxicity models (e.g. 3D models and MEA electrophysiology) and PBPK/QSAR modelling expertise. As well as supporting clients directly, we have a strong focus on R&D and our scientists regularly present our findings at scientific conferences and through publications.
Our laboratory is supported by a team of software engineers who work with the scientists to improve efficiency through LabSysTM, an internally built LIMS (laboratory information management system). This system provides support for compound registration, plate mapping, bar code reading, liquid handling and analytical automation as well as data processing. As we operate as a Contract Research Organisation, the quality of the data we generate is of paramount importance. Cyprotex has an internal quality system which covers SOPs, change management, exception reporting, training and incident reporting.
In August 2017, Evotec acquired Aptuit in order to further expand the Group’s capabilities. As well as additional complementary drug discovery capabilities, Aptuit offers full CMC and IND-enabling services allowing the Evotec Group to provide expert support across the value chain from early discovery through to preclinical development and beyond.
Cell viability assessment
In addition to multi-parametric cytotoxicity assessment using high content screening, Cyprotex offer general cell viability assessment using single endpoints such as LDH (lactate dehydrogenase), neutral red or MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide).
Through its acquisition of the business and assets of CeeTox in January 2014, Cyprotex can offer a range of services to evaluate skin sensitization. These include the Direct Peptide Reactivity Assay (DPRA), the KeratinoSens™ and the SenCeeTox assays.
Understand the potenial irritation to the eye of your individual ingredients / chemicals or finished products using our ocular irritation assay.
Ocular irritation is in our portfolio of in vitro topical services for the cosmetics/personal care, chemical or pharmaceutical industry. Cyprotex deliver consistent, high quality data under either GLP or non-GLP conditions.
Ocular irritation and its measurement in vitro
Cyprotex’s ocular irritation test is performed using MatTek's in vitro 3D EpiOcular™ model. Cyprotex are a MatTek-approved laboratory for performing these studies.
The EpiOcular™ tissue model consists of normal, human-derived epidermal keratinocytes that have been cultured to form a stratified, squamous epithelium which closely mimics the human corneal epithelium.
EpiOcular™ was developed by MatTek to create an in vitro (non-animal) alternative to the animal-based Draize Eye Irritation Test used in the cosmetics, personal care, household products, chemical, pharmaceutical, and biotech industries.
The EpiOcular™ eye irritation test model is currently undergoing ECVAM validation. Peer-reviewed publications have shown the EpiOcular™ eye irritation model achieves greater than 80% accuracy when compared with the Draize eye irritation test.
The EpiOcular™ model is metabolically and mitotically active and produces the same cytokines involved in irritation and inflammation in vivo.
A range of different test articles can be assessed including liquids, solids, semi-solids, pastes, gels, creams and waxes.
Cyprotex's ocular irritation test is based upon assessment of the cytotoxicity following exposure to a test chemical, typically at three time points. Cytotoxicity is expressed as a decrease in mitochondrial conversion of MTT to formazan.
Through its acquisition of the business and assets of CeeTox in January 2014, Cyprotex can offer a range of services to evaluate skin sensitization. These include the Direct Peptide Reactivity Assay (DPRA), the KeratinoSens™ and the SenCeeTox assays.
Cyprotex’s skin irritation test is performed using MatTek's in vitro 3D human skin tissue model (EpiDerm™). Cyprotex are a MatTek-approved laboratory for performing these studies.
Contact us to find out more about our dermal penetration and toxicity services.
The EpiDerm™ tissue model, which closely mimics human epidermis, was developed by MatTek to create an in vitro (non-animal) alternative to the animal-based Draize Skin Irritation Test used in the cosmetics, personal care, household products, chemical, pharmaceutical, and biotech industries.
The scientific validity of the EpiDerm™ skin irritation test model has been endorsed by the ECVAM Scientific Advisory Committee (ESAC) as an in vitro replacement for the Draize Skin Irritation Test. This led to the adoption of the OECD Test guidelines 439 which were published in 2010.
Cyprotex follows the standardized skin irritation test procedure within the OECD guidelines. Our skin irritation test results provide a robust assessment of skin irritation using a model accepted by the EU regulatory authorities.
Endocrine Disruption
Endocrine disruptors are chemicals that interfere with the hormonal system in the body which can lead to adverse effects on the developmental, reproductive, neurological and immune systems. Both natural and man-made chemicals are reported to cause endocrine disruption. These include pharmaceuticals (e.g., 17α-ethinyl estradiol), pesticides and herbicides (e.g., DDT), heavy metals (e.g., cadmium and lead), plasticisers (e.g., bisphenol A) and various other chemicals.
Endocrine disruptors are found in common everyday products such as metal food cans, plastic bottles, detergents, toys, cosmetics and pesticides. Although the link between endocrine disruptors and disease continues to be debated, epidemiological data show increases in incidence and prevalence of diseases associated with endocrine-disrupting chemicals, such as breast, prostate, and testis cancer, diabetes, obesity, and decreased fertility over the last 50 years. There is particular concern regarding low levels of environmental chemical and their effects on foetal development and on the behaviour or development of children.
Chemicals can disrupt the endocrine system via a variety of mechanisms including:
Through its acquisition of the business and assets of CeeTox in January 2014, Cyprotex can now offer a range of services to evaluate endocrine disruption which include standard screening assays as well as services compliant with the US EPA Endocrine Disruption Screening Program (EDSP).
Our in vitro ADME and DMPK services include in vitro metabolism, in vitro permeability and transporters, solubility and physicochemical properties, in vitro protein binding and PK and bioanalysis
Metabolite Profiling and Identification using High Resolution Accurate Mass Spectrometry
Understand the drug metabolism of your compound by identifying which metabolites are formed during in vitro or in vivo studies. Metabolite profiling and identification is included in Cyprotex's portfolio of ADME services. Cyprotex delivers consistent, high quality data in line with regulatory guidelines, and can adapt protocols based on specific customer requirements.
Profiling and identification of metabolites:
The parallel artificial membrane permeability assay is one of Cyprotex's in vitro ADME screening services. Cyprotex deliver consistent, high quality data with cost-efficiency that comes from a highly automated approach.
The Parallel Artificial Membrane Permeability Assay (PAMPA) is used as an in vitro model of passive, transcellular permeation.
Understand the potential drug-drug interaction liabilities of your compounds by using our cytochrome P450 (CYP450) reversible inhibition assay for a range of isoforms.
The cytochrome P450 inhibition assay is one of our portfolio of in vitro ADME screening services. Cyprotex delivers consistent, high quality data with cost-efficiency that comes from a highly automated approach.
Inhibition of cytochrome P450 (CYP450) enzymes
Cyprotex's Caco-2 Permeability assay uses an established method for predicting the in vivo absorption of drugs across the gut wall by measuring the rate of transport of a compound across the Caco-2 cell line.
Understand the potential drug-drug interaction liabilities of your compounds by using our cytochrome P450 (CYP450) induction assay.
Cytochrome P450 induction is one of Cyprotex's in vitro experimental ADME services. Cyprotex delivers consistent, high quality data with the flexibility to adapt protocols based on specific customer requirements.
Induction of cytochrome P450 enzymes is associated with an increased prevalence of clinical drug-drug interactions.
PXR and AhR Nuclear Receptor Activation
Monoamine oxidase (MAO) inhibition assay
Understand if your compound is an inhibitor of MAO-A or MAO-B enzyme. Monoamine oxidase (MAO) inhibition is a non-CYP mediated metabolism assay within our portfolio of in vitro ADME screening services. Cyprotex delivers consistent, high quality data with the flexibility to adapt protocols based on specific customer requirements.
Determining potential inhibition of MAO enzymes
High Content Toxicology: Cytotoxicity Screening Panel
Drug toxicity is often a combination of multiple mechanisms. A single experimental approach is unlikely to capture the complexity involved in cellular toxicity.
Plasma Protein Binding Assay
Understand the distribution potential of your compound using our plasma protein binding assay.
Plasma protein binding is one of Cyprotex's in vitro ADME screening services. Cyprotex deliver consistent, high quality data with cost-efficiency that comes from a highly automated approach.
Determination of fraction unbound in plasma using equilibrium dialysis:
Turbidimetric Solubility Assay
Understand if poor solubility is likely to be an issue in the development of your compound.
Turbidimetric solubility is one of Cyprotex's in vitro ADME screening services. Cyprotex delivers consistent, high quality data with cost-efficiency that comes from a highly automated approach.
The role of turbidimetric solubility measurement in early discovery:
Plasma stability assay
Use our plasma stability assay to measure the degradation of your compounds in plasma.
The plasma stability assay is one of Cyprotex's in vitro ADME screening services. Cyprotex deliver consistent, high quality data with cost-efficiency that comes from a highly automated approach.
Determination of stability in plasma
Our biosciences division focuses on efficacy screening using cell based assays. We specialize in 2D and 3D cell-based approaches and have expertise in a wide range of techniques to cover phenotypic-based screening, target-based screening, and exploratory biology and mechanistic studies.
Our biosciences division focuses on efficacy screening using cell based assays. We specialize in 2D and 3D cell-based approaches and have expertise in a wide range of techniques to cover phenotypic-based screening, target-based screening, and exploratory biology and mechanistic studies.
Electrophysiology Services
Product Testing Services
Drug Permeability Studies Services
Cyprotex US, LLC has not received any reviews.
Cyprotex US, LLC has not received any endorsements.